Sanofi-Aventis takes control of Genzyme
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis finally has control of Genzyme. Having completed its exchange offer, it now holds 84.6% of Genzyme's outstanding shares of common stock, or 77% of the shares on a fully diluted basis.